AUA 2013: Early steps taken in using stem cells for infertility
Wake Forest University researchers have conducted early, pre-clinical work that they say supports further research on the use of spermatogonial stem cell (SSC) transplantation as a potential treatment for male infertility.
SSC autotransplantation would play a particularly important role in pediatric cancer patients undergoing chemotherapy or radiation therapy, in whom sterility cannot be prevented and who have no means available to preserve fertility, said John D. Jackson, PhD, of the Wake Forest University School of Medicine and the Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC.
The research is being led by Anthony Atala, MD, and Hooman Sadri-Ardekani, PhD. Dr. Sadri-Ardekani has developed a culture technique aimed at propogating stem cells, and the researchers are in the process of characterizing those cells using a panel of three phenotype markers.
“The only way to truly identify a stem cell is to go back into a human and show that you get repopulation of cells. But you can use these other assays as surrogates,” Dr. Johnson said.
In the current study, adult cadaveric human testicular tissues were received from three individuals, and the tissues were immediately cryopreserved. After thawing and enzymatic digestion, the testicular cells were seeded. The presence of spermatogonial cells and their quantity were evaluated by germ line stem cell (GSC) formation, reverse transcriptase (RT) PCR, and flow cytometry.
The first GSC cluster formation was seen after 2 weeks of culture, Dr. Johnson reported. RT PCR for PLZF (ZBTB16), UCHL1 (PGP 9.5), FGFR3, and CD9 as markers for undifferentiated spermatogonial cells (including SSCs) confirmed the presence of these cells during the culture period. Flow cytometric analyses showed various percentages (0.7%-6%) of HLA-ABC-negative/FGFR3-positive cells (spermatogonial cells) in different passages during the culture period.
“We’re in the very early stages. Clinical trials haven’t been started. We’re collecting tissue now under an approved IRB,” Dr. Johnson said.
MORE ARTICLES IN THIS ISSUE
Trigonal onabotulinumtoxinA (Botox) brings equal analgesic relief to patients with ulcerative and non-ulcerative forms of bladder pain syndrome/interstitial cystitis (BPS/IC) alike, researchers say.
Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder (OAB) who are poor responders to antimuscarinic agents or intolerant of their adverse events.
New evidence from the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.
Building on previous research suggesting a cause-and-effect link between mental illness and urinary dysfunction, a new study finds that older men with two or more lower urinary tract symptoms are more likely to have recently had thoughts of suicide.
Men with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.